Health & Fitness
Thu, March 31, 2011Wed, March 30, 2011Tue, March 29, 2011Mon, March 28, 2011Sun, March 27, 2011Fri, March 25, 2011Thu, March 24, 2011Wed, March 23, 2011Tue, March 22, 2011Mon, March 21, 2011Sun, March 20, 2011Fri, March 18, 2011Thu, March 17, 2011Wed, March 16, 2011Tue, March 15, 2011Mon, March 14, 2011Sun, March 13, 2011Sat, March 12, 2011Fri, March 11, 2011Thu, March 10, 2011Biotech Sector Is a Hotbed of Takeover Speculation
Published in Health and Fitness on Monday, March 21st 2011 at 5:05 GMT by Market Wire
NEW YORK, NY--(Marketwire - March 21, 2011) - M&A activity in the healthcare sector has been on the upswing in recent quarters. Going forward larger healthcare firms are expected to continue searching for smaller, more speculative companies which are focusing on specific treatments and specialties in the medical sector. Recent reports suggest that not only is Big Pharma active in acquisitions, but also larger biotech firms are showing willingness to utilize their large resource pools to acquire smaller firms in a race to diversify and to build their reach. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Xoma Ltd. (
[ www.bedfordreport.com/2011-03-XOMA ]
[ www.bedfordreport.com/2011-03-HGSI ]
A recent report from Deal Search Online claims that while the biotech sector saw a 40 percent drop in the number of M&A deals last year, the 115 deals in 2010 amounted to $57.5 billion, a 21 percent increase over 2009. The report suggests that the last decade saw an increase in the amount of biotech deals, led in part by pharmaceutical companies seeking new blockbuster drugs to fill the void left by drugs coming off patent.
The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous analyst reports and industry newsletters.
Recently the FDA approved Human Genome Sciences' Lupus Drug, Benlysta. Prior to Benlysta, the FDA last approved drugs to treat lupus, Plaquenil (hydroxychloroquine) and corticosteroids, in 1955. Aspirin was approved to treat lupus in 1948. GlaxoSmithKline has a 50-50 development and marketing partnership with HGSI for Benlysta, leading many analysts to speculate that Human Genome Sciencesis a likely takeover target for Glaxo.
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at [ http://www.bedfordreport.com/disclaimer ]
